Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Recombinant influenza vaccines Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702
View directory record Official record
Conditions
Influenza, Human
Interventions
Investigational aIIV4c, IIV4c, aIIV4, RIV4
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

NCT02285998
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
9,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

NCT00966238
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Lanexa, Kansas • Rochester, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Open-Label Influenza Vaccine Evaluation

NCT02872311
View directory record Official record
Conditions
Immune Response
Interventions
High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
65 Years to 74 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

NCT01658800
View directory record Official record
Conditions
Influenza
Interventions
VAX161C vaccine
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
South Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

NCT00539864
View directory record Official record
Conditions
Influenza
Interventions
FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years to 64 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Fresno, California • Hayward, California • Roseville, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00003792
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Baylor Health Care System
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

NCT00722774
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H2N2 1960 AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2008 · Synced Oct 9, 2026, 2:26 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137
View directory record Official record
Conditions
COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

NCT00539981
View directory record Official record
Conditions
Influenza
Interventions
FluBlok®, Placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
24
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Vaccine for Prevention of Bird Flu

NCT00776711
View directory record Official record
Conditions
Influenza, Human
Interventions
Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

NCT03283319
View directory record Official record
Conditions
Influenza, Human
Interventions
3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7, MF59, AS03
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

NCT05945485
View directory record Official record
Conditions
Influenza
Interventions
DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 9, 2026, 2:26 AM EDT
Withdrawn Phase 2 Interventional

High Dose Influenza in Immunosuppressed Subjects

NCT00766285
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

NCT04622592
View directory record Official record
Conditions
Influenza
Interventions
Instramuscular vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
14
States / cities
Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 9, 2026, 2:26 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Lenexa, Kansas • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

NCT05375838
View directory record Official record
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1073, mRNA-1010, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
14
States / cities
Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influenza Antiviral DAS-181-F04 in Healthy Adults

NCT01651494
View directory record Official record
Conditions
Influenza
Interventions
DAS181, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

NCT02274545
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 9, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of RIV4 Versus IIV4 in Pregnant Women

NCT03969641
View directory record Official record
Conditions
Safety, Adverse Event Following Immunisation, Birth Outcomes
Interventions
Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 9, 2026, 2:26 AM EDT